Ischemic injury inevitably occurs during the procurement of organs for transplantation, and the injury is worsened by inflammation following reperfusion. The purpose of this review is to describe the role of the innate immune system in ischemia-induced renal injury in kidneys procured for transplantation. The key role of pattern recognition receptors in immune responses to ischemia is described. Innate immune receptors are emerging novel targets for the amelioration of ischemic injury of donor kidneys.
INTRODUCTION
Ischemia plays a major role in the initial injury and eventual outcomes of transplanted kidneys. Ischemic injury is of course unavoidable, because of the need to disrupt the renal vasculature during the process of transplantation, and it is worsened by events that occur before and after organ procurement. Donor-specific events (e.g., brain death, renal hypoperfusion, nephrotoxins, cold and warm ischemia, etc.) compound the ischemic insult. After transplantation, a potent inflammatory response mounted by the recipient's immune system can cause even more damage. Many studies have shown that the severity of the ischemia-reperfusion injury during the early stages of transplantation ultimately determines long-term graft function [1] . This review discusses emerging concepts that have the potential to lead to new targets for the amelioration of ischemic kidney injury.
Renal tubular epithelial (RTE) cells, particularly those in the S3 segment of the proximal tubule and medullary thick ascending limb of the loop of Henle, exist in a hypoxic microenvironment. Therefore, it is no surprise that this region of the kidney is significantly impacted by a decrease in oxygen delivery. Upon disruption of the donor vasculature, the ischemic RTE cells release their intracellular contents ( Fig. 1 ) triggering a potent sterile inflammatory response that causes a cascade of injurious events ultimately impacting the survival of the transplanted kidney. Abundant data have shown that RTE cells, interstitial dendritic cells, and endothelial cells in the kidney express receptors of the innate immune system, called pattern recognition receptors (PRRs), which are exquisitely sensitive to molecular patterns [danger activated molecular patterns (DAMPs)], such as those found
INNATE IMMUNE RECEPTORS IN THE KIDNEY
Among the best-characterized PRRs in the kidney are the toll-like receptors (TLRs) (Fig. 2) . TLRs are transmembrane receptors constitutively expressed on immune and parenchymal cells in rodents and humans. Different TLRs, including TLR1-4, TLR6, and TLR9, have been documented on RTE cells [3] [4] [5] [6] . TLRs2, 4, and 3 are also expressed on endothelial cells, mesangial cells, and podocytes [4, [7] [8] [9] [10] [11] , and TLRs5 and 11 have been found on distal renal tubules and bladder epithelium [12, 13] . In humans, TLR9 and TLR7 have also been found within the kidney and are particularly important in models of nephritis and inflammation in the kidney [14, 15] . Polymorphisms in TLR3 have been associated with delayed graft function in humans [16] and TLR4 has been shown to be upregulated in kidneys from deceased donors [17] and contribute to ischemia-reperfusion injury [18] . Recipients or donors with TLR4 loss-of-function polymorphisms
KEY POINTS
The pathophysiological events associated with ischemia/reperfusion injury have their origin in signals derived from PRRs expressed in the donor kidney.
DAMPs released from injured cells serve as ligands for PRRs expressed on many cells in the donor kidney.
Both membrane-bound PRRs (e.g., TLRs) and intracytoplasmic PRRs (e.g., NLRs) are expressed throughout the normal kidney.
Activation of PRR signaling in the donor kidney leads to production of proinflammatory cytokines and chemokines as well as cell death signaling, ultimately worsening the initial ischemic injury.
New therapies targeting PRRs in the kidney are likely to provide novel approaches to prevent or treat ischemic renal disease. 
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have been reported to have fewer acute rejection episodes [19, 20] although others have found no association [21] .
NOD-LIKE RECEPTORS
Another family of PRRs has emerged as important in the kidney, the nucleotide binding, leucine-rich repeat containing receptors (NLRs) (Fig. 2) The noninflammasome family mediates their function through nuclear factor kappa-light-chainenhancer of activated B cells (NF-kB) activation, whereas the inflammasome family relies on caspase-1. CIITA functions as a transcription factor for major histocompatibility complex (MHC)II expression [23] . Both NOD and NLRP family members are expressed in murine and human RTE cells [24] [25] [26] .
The best-characterized NOD/noninflammasome family members in renal ischemia reperfusion injury (IRI) are NOD1 and NOD2. NOD1 and NOD2 activation leads to the production of proinflammatory factors [e.g., interleukin (IL)-6, chemokine (C-X-C motif) ligand (CXCL)3, CXCL1, macrophage inflammatory protein 2-alpha (MIP2; also called CXCL2 in humans), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (Cox-2)] and neutrophil recruitment, worsening ischemic tissue damage and cell death [27] [28] [29] [30] [31] . Disruption of either NOD1 or NOD2 signaling diminishes inflammation in renal IRI. NOD1 and NOD2 are expressed on both leukocytes and parenchymal cells, and simultaneous elimination of NOD1 and NOD2 affords increased protection over the single knockouts [24] .
The NOD-leucine-rich repeat pyrin domain containing (NLRP) or inflammasome NLR family also plays an important role in renal IRI. The NLRP family forms inflammasome complexes by recruiting apoptosis-associated speck-like protein, and caspase-1 [32] . Unlike the TLRs or NODs, which are characterized by induction of NF-kB and mitogenactivated protein kinase, the inflammasomes induce cleavage of pro-IL-1b and pro-IL-18 to their active forms by activating caspase-1. The inflammasomes are triggered by many different molecules that are released from ischemic RTE cells making 
PATTERN RECOGNITION RECEPTOR INDUCTION OF CELL DEATH SIGNALING
Many studies have shown that PRR activation can induce cell death signaling pathways, leading to apoptosis and necrosis. Apoptosis (characterized by cell shrinkage, chromatin condensation, membrane blebbing, and nuclear fragmentation) is because of proteolytic activity of caspases and is a regulated, metabolically controlled form of cell death that preserves membrane integrity [35] . Endogenous molecules such as ATP and histones released by dying cells can stimulate apoptosis through PRR ligation [36] [37] [38] [39] . Recent studies have also shown that the blocking of apoptosis or components of apoptotic signaling can prevent ischemic renal injury [38, [40] [41] [42] [43] [44] .
NECROSIS
Necrotic cell death is also regulated by PRRs and is characterized by loss of cell membrane integrity and swelling of mitochondria and intracellular organelles. Necrosis is induced by several PRRmediated intracellular signaling pathways that lead to distinct types of necrotic cell death, which are described below.
Pyroptosis
Pyroptosis is a type of regulated cell necrosis characterized by the formation of plasma membrane pores and cell membrane rupture, without nuclear or mitochondrial damage. It is typically triggered by TLRs and NLRs [45
&&
]. Ligation of these PRRs can result in the formation of two different cytosolic scaffolds, an NLRP3-containing inflammasome and a pyroptosome (which is independent of NLRP3). Similar to apoptosis, pyroptosis requires activation of caspase-1, but, unlike apoptosis, it does not require any other of the classical caspases involved in cell death [46, 47] . This form of cell death has been shown to be important in ischemic injury of the liver [ . It is clear that ischemic injury can induce necroptosis in the kidney, and blocking RIP3 was shown in one study to partially ameliorate IR injury [52] . Necrostatin-1, a blocker of the necroptosome, has also been shown to decrease renal IR injury [53] . Necroptosis can be attenuated by small molecule inhibitors such as necrosulfonamide, which binds and inactivates the executioner molecule, mixed lineage kinase like (psedo) kinase (MLKL); this is the effector of necroptosis-induced plasma membrane rupture [54] . Clinical targets for the necroptosome are not yet available.
Other forms of necrosis
Several other forms of nonapoptotic (necrotic) orchestrated cell death, each with their own unique biochemical and morphological features, can play a role in ischemic death in the kidney. Parthanatos, a form of caspase-independent cell death is mediated by poly (ADP-ribose) polymerase (PARP), an enzyme involved in the DNA repair process. PARP is one of the most abundant proteins in the nucleus and hyperactivation of PARP results in nicotinamide adenine dinucleotide (NAD) depletion and subsequent impairment of ATP-generating glycolysis, ultimately leading to necrotic cell death. PARP-1 inhibitors can provide protection in rat models of ischemia/reperfusion injury [55] , although there is likely overlap between necroptotic and PARP-1-mediated processes [56] .
Another form of programmed cell death called ferroptosis is because of iron-dependent reactive oxygen species (ROS) and lipid peroxide accumulation [57] . In contrast to necroptosis, ferroptosis causes necrosis of renal tubules ex vivo and blockade of ferroptosis provides highly significant protection from ischemic renal tubular injury [58] . Finally, incomplete autophagy may cause cell death through a process called autosis [45 && ]. Autosis is characterized by the accumulation of vacuoles at the nuclear membrane and endoplasmic reticulum rupture. Autosis has been shown to occur in the ischemic brain of rodents in vivo [59] , but little is known about its role in renal ischemia.
INFLAMMATION AS A CONSEQUENCE OF ISCHEMIA
Once the vascular anastomosis is complete, the inflammatory milieu of the donor organ, induced by ischemia-mediated cell death, directs a potent recipient immune response. In the absence of immunosuppressant medications, this inflammatory response will lead to destruction of the allograft. As mentioned above, intracellular contents released by the necrotic cells as a result of ischemia are thought to be the triggers of the innate and adaptive effectors, through the induction of proinflammatory cytokines/chemokines and type 1 interferons [60] . Many studies in humans and rodents have shown that immune effector cells, such as neutrophils, macrophages/monocytes, and dendritic cells promote further damage by inducing cell death through ROS and activating caspases [61] [62] [63] . RTE cells are capable of directly contributing to the inflammatory reaction by stimulating resident T cells. MHC class II and costimulatory molecule expression is upregulated on RTE cells through PRR-induced type 1 interferons [64] . Although many reports suggest activated RTE cells can act as nonprofessional-antigen presenting cells to simulate cluster of differentiation (CD)4 þ and cytotoxic CD8
þ T cells [65, 66] , some recent reports indicate that they suppress not only alloreactive human T-cell responses but also B-cell responses [67,68 & ]. Therefore, further studies need to be performed to address the contrasting nature of RTE cells in activating murine and human T and B-cell responses.
IMMUNE CELLS INVOLVED IN INFLAMMATORY RESPONSE
Inflammatory cells of the recipient that are recruited to the donor kidney worsen the initial ischemic injury. Neutrophils release proteases, ROS, cytokines, and chemokines. This potent inflammatory cocktail further increases vascular permeability and reduces tubule epithelial and endothelial cell integrity [69] . Neutrophil recruitment is mediated by adhesion molecules, including intercellular adhesion molecule (ICAM)-1, selectins, and CD11/ CD18 [70] . Macrophages also accumulate in the kidney following IRI, although there have been conflicting studies over whether they are indeed detrimental [70] [71] [72] . A recent study showed that diphtheria-toxin-CD11b treated mice were not protected from renal IRI, whereas clodronate depletion resulted in improved renal function [73] . These results suggest that a protective macrophage population, in addition to the conventional inflammatory population, might exist.
Dendritic cells, along with macrophages, are one of the early initiators of innate immunity; dendritic cells are crucial cells involved in bridging the innate and adaptive arms of immune system. Dendritic cells are known to abundantly express PRRs and are implicated in dendritic cell activation after IR injury. Activated dendritic cells function as professional antigen-presenting cells and propagate inflammatory responses through direct activation of T cells or indirectly through cytokine secretion [62] . The extent of dendritic cell function in renal IR injury was described in a recent study, where it was shown that preventing dendritic cell maturation exerted a therapeutic immunosuppressive effect in renal IR injury [74] . Although dendritic cells activate the adaptive immune system, they can also induce tolerance and inhibit inflammatory responses [75] . In a recent study dendritic cells tolerized with adenosine 2A receptor agonists attenuated renal IRI by suppressing natural killer T-cell (NKT) activation [76] .
Other cell types also appear to be important during the reperfusion phase, including NKT cells and T regulatory cells (Tregs). NKT cells are a subset of T cells expressing the T-cell receptor and the surface molecule NK1.1. NKT cells are activated by endogenous and exogenous glycolipids presented by CD1 expressing dendritic cells [77] . Upon activation, they produce interferon (IFN)-g, tumor necrosis factor (TNF)-a, IL-4, and IL-1b. Following reperfusion, the numbers of NKT cells have been shown to increase in the kidney [77] . Blocking or depleting NKT cells prevents neutrophil recruitment and kidney injury, demonstrating a potential role of NKT function in neutrophil recruitment [77] . Tregs play a vital role in suppressing the inflammation mediated by innate effector cells. Following injury, Tregs traffic to the kidney [78] and mediate suppression through the release of the anti-inflammatory cytokine IL-10 [79] . Mice lacking Tregs have greater numbers of inflammatory leukocytes in the kidney following injury and increased renal damage [78, 79] . B lymphocytes are also thought to participate in the early phases of renal IR injury [80] . B cells are believed to have an effect during the recovery phase of the renal injury and recent studies of renal transplantation correlates the presence of mature B cells with decreased renal graft survival [81] . A recent report suggests that innate immune activation in kidney after IR injury effects systemic B lymphocytes and production of harmful antibodies, and that the absence of B cells alleviates IR injury and promotes renal tubule regeneration [82] .
CONCLUSION
Renal transplantation offers improved survival and quality of life for patients with end stage renal disease. The length of donor organ survival though is limited by any ischemic injury that occurs during allograft procurement. Graft ischemia causes a sterile inflammatory response that has its origins in DAMPs, which are ligands for constitutively expressed PRRs on many cells in the kidney, including RTE cells, interstitial dendritic cells and endothelial cells. Activation of PRR signaling pathways trigger secretion of proinflammatory molecules, and they also extend cell death directly by induction of apoptotic and necrotic signaling pathways. There is much interest in defining the expression and regulation of PRRs in the kidney to develop targeted therapies to prevent the downstream consequences of ischemic donor allograft injury. New investigation therapies, targeting the PRR activation of innate immunity during ischemia, may not only prevent early stages of ischemic injury by decreasing local RTE cell injury promoting cell death but may also prevent the host inflammatory response after transplantation.
